Relevant bibliographies by topics / CRISPR-associated protein 9

Contents

  1. Journal articles
  2. Reports

Academic literature on the topic 'CRISPR-associated protein 9'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CRISPR-associated protein 9.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CRISPR-associated protein 9"

1

Chaturvedi, Sarika, and Jinny Tomar. "CRISPR/CAS 9 Mediated Treatment for UTIs." International Journal for Modern Trends in Science and Technology 6, no. 5 (May 31, 2020): 82–94. http://dx.doi.org/10.46501/ijmtst060515.

Full text
Abstract:
“CRISPR" is short and used for "CRISPR-Cas9. CRISPR stands for clustered regularly interspaced short palindromic repeats. CRISPRs are specialized stretches of DNA. The protein Cas9 (or "CRISPR-associated") is an enzyme that acts like a pair of molecular scissors, capable of cutting strands of DNA and can be used in conjunction with engineered CRISPR sequences to hunt down codes and slice into them like a molecular scalpel, allowing geneticists to cut out a target gene, either to remove it or replace it with a new sequence. Therefore it is a simple and powerful tool for editing genomes to easily alter DNA sequences and amend gene function. In 1987, The CRISPR locus was first identified in Escherichia coli and discovered when a genetic structure containing 5 highly homologous repeats of 29 nucleotides separated by 32-nucleotide spacers (Ishino Y 1987).
APA, Harvard, Vancouver, ISO, and other styles
2

Gong, Yan, Siyu Tian, Yang Xuan, and Shubiao Zhang. "Lipid and polymer mediated CRISPR/Cas9 gene editing." Journal of Materials Chemistry B 8, no. 20 (2020): 4369–86. http://dx.doi.org/10.1039/d0tb00207k.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nomura, Toshihisa, Mizuki Yoshikawa, Kengo Suzuki, and Keiichi Mochida. "Highly Efficient CRISPR-Associated Protein 9 Ribonucleoprotein-Based Genome Editing in Euglena gracilis." STAR Protocols 1, no. 1 (June 2020): 100023. http://dx.doi.org/10.1016/j.xpro.2020.100023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Aalipour, Amin, Jonathan C. Dudley, Seung-min Park, Surya Murty, Jacob J. Chabon, Evan A. Boyle, Maximilian Diehn, and Sanjiv S. Gambhir. "Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA." Clinical Chemistry 64, no. 2 (February 1, 2018): 307–16. http://dx.doi.org/10.1373/clinchem.2017.278911.

Full text
Abstract:
Abstract BACKGROUND Cell-free DNA (cfDNA) diagnostics are emerging as a new paradigm of disease monitoring and therapy management. The clinical utility of these diagnostics is relatively limited by a low signal-to-noise ratio, such as with low allele frequency (AF) mutations in cancer. While enriching for rare alleles to increase their AF before sample analysis is one strategy that can greatly improve detection capability, current methods are limited in their generalizability, ease of use, and applicability to point mutations. METHODS Leveraging the robust single-base-pair specificity and generalizability of the CRISPR associated protein 9 (Cas9) system, we developed a deactivated Cas9 (dCas9)-based method of minor-allele enrichment capable of efficient single-target and multiplexed enrichment. The dCas9 protein was complexed with single guide RNAs targeted to mutations of interest and incubated with cfDNA samples containing mutant strands at low abundance. Mutation-bound dCas9 complexes were isolated, dissociated, and the captured DNA purified for downstream use. RESULTS Targeting the 3 most common epidermal growth factor receptor mutations (exon 19 deletion, T790M, L858R) found in non-small cell lung cancer (NSCLC), we achieved >20-fold increases in AF and detected mutations by use of qPCR at an AF of 0.1%. In a cohort of 18 NSCLC patient-derived cfDNA samples, our method enabled detection of 8 out of 13 mutations that were otherwise undetected by qPCR. CONCLUSIONS The dCas9 method provides an important application of the CRISPR/Cas9 system outside the realm of genome editing and can provide a step forward for the detection capability of cfDNA diagnostics.
APA, Harvard, Vancouver, ISO, and other styles
5

Kato-Inui, Tomoko, Gou Takahashi, Szuyin Hsu, and Yuichiro Miyaoka. "Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 with improved proof-reading enhances homology-directed repair." Nucleic Acids Research 46, no. 9 (April 17, 2018): 4677–88. http://dx.doi.org/10.1093/nar/gky264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lentsch, Eva, Lifei Li, Susanne Pfeffer, Arif B. Ekici, Leila Taher, Christian Pilarsky, and Robert Grützmann. "CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines." International Journal of Molecular Sciences 20, no. 22 (November 14, 2019): 5706. http://dx.doi.org/10.3390/ijms20225706.

Full text
Abstract:
In 90% of pancreatic ductal adenocarcinoma cases, genetic alteration of the proto-oncogene Kras has occurred, leading to uncontrolled proliferation of cancerous cells. Targeting Kras has proven to be difficult and the battle against pancreatic cancer is ongoing. A promising approach to combat cancer was the discovery of the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system, which can be used to genetically modify cells. To assess the potential of a CRISPR/CRISPR-associated protein 9 (Cas9) method to eliminate Kras mutations in cells, we aimed to knock-out the c.35G>A (p.G12D) Kras mutation. Therefore, three cell lines with a heterozygous Kras mutation (the human cell lines SUIT-2 and Panc-1 and the cell line TB32047 from a KPC mouse model) were used. After transfection, puromycin selection and single-cell cloning, proteins from two negative controls and five to seven clones were isolated to verify the knock-out and to analyze changes in key signal transduction proteins. Western blots showed a specific knock-out in the KrasG12D protein, but wildtype Kras was expressed by all of the cells. Signal transduction analysis (for Erk, Akt, Stat3, AMPKα, and c-myc) revealed expression levels similar to the wildtype. The results described herein indicate that knocking-out the KrasG12D mutation by CRISPR/Cas9 is possible. Additionally, under regular growth conditions, the knock-out clones resembled wildtype cells.
APA, Harvard, Vancouver, ISO, and other styles
7

Lone, Bilal Ahmad, Shibendra Kumar Lal Karna, Faiz Ahmad, Nerina Shahi, and Yuba Raj Pokharel. "CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering." Genetics Research International 2018 (September 18, 2018): 1–17. http://dx.doi.org/10.1155/2018/3797214.

Full text
Abstract:
Microbes use diverse defence strategies that allow them to withstand exposure to a variety of genome invaders such as bacteriophages and plasmids. One such defence strategy is the use of RNA guided endonuclease called CRISPR-associated (Cas) 9 protein. The Cas9 protein, derived from type II CRISPR/Cas system, has been adapted as a versatile tool for genome targeting and engineering due to its simplicity and high efficiency over the earlier tools such as ZFNs and TALENs. With recent advancements, CRISPR/Cas9 technology has emerged as a revolutionary tool for modulating the genome in living cells and inspires innovative translational applications in different fields. In this paper we review the developments and its potential uses in the CRISPR/Cas9 technology as well as recent advancements in genome engineering using CRISPR/Cas9.
APA, Harvard, Vancouver, ISO, and other styles
8

Xia, An-Liang, Qi-Feng He, Jin-Cheng Wang, Jing Zhu, Ye-Qin Sha, Beicheng Sun, and Xiao-Jie Lu. "Applications and advances of CRISPR-Cas9 in cancer immunotherapy." Journal of Medical Genetics 56, no. 1 (July 3, 2018): 4–9. http://dx.doi.org/10.1136/jmedgenet-2018-105422.

Full text
Abstract:
Immunotherapy has emerged as one of the most promising therapeutic strategies in cancer. The clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (CRISPR-Cas9) system, as an RNA-guided genome editing technology, is triggering a revolutionary change in cancer immunotherapy. With its versatility and ease of use, CRISPR-Cas9 can be implemented to fuel the production of therapeutic immune cells, such as construction of chimeric antigen receptor T (CAR-T) cells and programmed cell death protein 1 knockout. Therefore, CRISPR-Cas9 technology holds great promise in cancer immunotherapy. In this review, we will introduce the origin, development and mechanism of CRISPR-Cas9. Also, we will focus on its various applications in cancer immunotherapy, especially CAR-T cell-based immunotherapy, and discuss the potential challenges it faces.
APA, Harvard, Vancouver, ISO, and other styles
9

Cao, Hieu X., Wenqin Wang, Hien T. T. Le, and Giang T. H. Vu. "The Power of CRISPR-Cas9-Induced Genome Editing to Speed Up Plant Breeding." International Journal of Genomics 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/5078796.

Full text
Abstract:
Genome editing with engineered nucleases enabling site-directed sequence modifications bears a great potential for advanced plant breeding and crop protection. Remarkably, the RNA-guided endonuclease technology (RGEN) based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) is an extremely powerful and easy tool that revolutionizes both basic research and plant breeding. Here, we review the major technical advances and recent applications of the CRISPR-Cas9 system for manipulation of model and crop plant genomes. We also discuss the future prospects of this technology in molecular plant breeding.
APA, Harvard, Vancouver, ISO, and other styles
10

Horodecka, Katarzyna, and Markus Düchler. "CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles." International Journal of Molecular Sciences 22, no. 11 (June 4, 2021): 6072. http://dx.doi.org/10.3390/ijms22116072.

Full text
Abstract:
The establishment of CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) technology for eukaryotic gene editing opened up new avenues not only for the analysis of gene function but also for therapeutic interventions. While the original methodology allowed for targeted gene disruption, recent technological advancements yielded a rich assortment of tools to modify genes and gene expression in various ways. Currently, clinical applications of this technology fell short of expectations mainly due to problems with the efficient and safe delivery of CRISPR/Cas9 components to living organisms. The targeted in vivo delivery of therapeutic nucleic acids and proteins remain technically challenging and further limitations emerge, for instance, by unwanted off-target effects, immune reactions, toxicity, or rapid degradation of the transfer vehicles. One approach that might overcome many of these limitations employs extracellular vesicles as intercellular delivery devices. In this review, we first introduce the CRISPR/Cas9 system and its latest advancements, outline major applications, and summarize the current state of the art technology using exosomes or microvesicles for transporting CRISPR/Cas9 constituents into eukaryotic cells.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Reports on the topic "CRISPR-associated protein 9"

1

Gong, Ping. Invasive species management on military lands : clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9)-based gene drives. Environmental Laboratory (U.S.), July 2017. http://dx.doi.org/10.21079/11681/22721.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'CRISPR-associated protein 9' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography